Forest/Cypress milnacipran for fibromyalgia:
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
First Phase III pivotal trial for Forest/Cypress Bioscience's fibromyalgia agent milnacipran is fully enrolled, Cypress announces Dec. 8. Initial results are expected in fall 2005. The second pivotal trial, being conducted by partner Forest, was launched in October. The Phase III program for the serotonin/norepinephrine reuptake inhibitor is expected to be complete in 2006. Forest and Cypress entered a $250 mil. development and marketing agreement in January. Another SNRI, Lilly's Cymbalta (duloxetine), is in Phase II development for fibromyalgia...